Skip to content
value.today
Intercept Pharmaceuticals logo

Intercept Pharmaceuticals

ICPTUnlisted company
$447 Mlast known market cap, Jul 2023 — no current value
Compare
World rank
—
no current market cap
Revenue
$286 M
For year ending December-2022
Net income
$222 M
77.6% margin
SEC filing
Employees
437
As on 2021
value.today research

Intercept Pharmaceuticals in brief

Intercept Pharmaceuticals is an unlisted company in the Biotechnology industry, based in New York, USA. It was founded in 2002. In the year to December 2022 it had sales of $286 M and a net profit of $222 M, about 78 cents of profit for every dollar of sales. It employs about 437 people.

Written from the figures on this page, so it changes when they do. The date of each figure is under How current the figures are.

About Intercept Pharmaceuticals

Intercept Pharmaceuticals, Inc. is an American biopharmaceutical company incorporated in 2002, focusing on the development of novel synthetic bile acid analogs to treat chronic liver diseases, such as primary biliary cirrhosis (PBC) now called primary biliary cholangitis, non-alcoholic fatty liver disease (or non-alcoholic steatohepatitis, NASH), cirrhosis, portal hypertension, primary sclerosing cholangitis and also the intestinal disorder, bile acid diarrhea.

From Wikipedia: read the full article · text available under CC BY-SA 4.0

Intercept Pharmaceuticals timeline

4 events, 2002–2022
  1. 2002
  2. 🏁
    · approximate
    Founded
  3. 2003
  4. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  5. 2012
  6. 🔔
    · approximate
    Initial public offering on Nasdaq
  7. 2022
  8. 💰
    Record revenue of $286 million
    FY2022, the highest of the 5 years on record.

Events of Intercept Pharmaceuticals from Wikidata, SEC EDGAR, the company record and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

More about Intercept Pharmaceuticals

Acquisitions and changes
Taken over: the company reported a change in control and the delisting of its shares to the SEC on 8 November 2023 (Form 8-K).

Market cap history

$0 M$1.1 B$2.1 B$3.2 B$4.3 B2020202120222023

World rank over time

▼ down 10,241 places since 2020
2020-01-01: #3217#3,21720202021-01-01: #8822#8,82220212022-01-07: #14284#14,28420222022-12-25: #12555#12,55520222023-07-30: #13458#13,4582023

Rank in USA: #1,043 (Jan 2020) · #2,364 (Jan 2021) · #3,043 (Jan 2022) · #2,620 (Dec 2022) · #2,796 (Jul 2023)

Key ratios

market cap and latest results · TTM = trailing 12 months
P/E ratio (TTM)
—
Price / sales (TTM)
—
Price / book
—
Free cash flow yield
—
Net margin (TTM)
77.6%
Operating margin
-23.9%
Return on equity
238.3%
Liabilities / assets
83.2%
Net debt
$173M
Revenue growth
+9.6%
R&D / revenue
61.8%
Revenue per employee
$654 K
Profit per employee
$508 K

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2015: revenue $3M, net income $-226M$3MFY15Fiscal year ending Dec 2016: revenue $25M, net income $-413M$25MFY16Fiscal year ending Dec 2017: revenue $131M, net income $-360M$131MFY17Fiscal year ending Dec 2018: revenue $180M, net income $-309M$180MFY18Fiscal year ending Dec 2019: revenue $252M, net income $-345M$252MFY19Fiscal year ending Dec 2020: revenue $234M, net income $-275M$234MFY20Fiscal year ending Dec 2021: revenue $261M, net income $-91M$261MFY21Fiscal year ending Dec 2022: revenue $286M, net income $222M$286MFY22
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2022$286M+9.6%$-68M$222M77.6%
Dec 2021$261M+11.4%$-100M$-91M-35.1%
Dec 2020$234M-7.2%$-230M$-275M-117.5%
Dec 2019$252M+40.2%$-312M$-345M-136.8%
Dec 2018$180M+37.3%$-285M$-309M-172.0%
Dec 2017$131M+424.9%$-336M$-360M-275.2%
Dec 2016$25M+797.5%$-403M$-413M-1654.6%
Dec 2015$3M—$-229M$-226M-8145.0%

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2022$-27M$1M$-27M$6.56—
Dec 2021$-41M$0M$-41M$-2.87—
Dec 2020$-172M$4M$-176M$-8.34—
Dec 2019$-237M$1M$-238M$-10.89—
Dec 2018$-241M$0M$-241M$-10.86—
Dec 2017$-265M$10M$-276M$-14.38—
Dec 2016$-342M$5M$-348M$-16.74—
Dec 2015$-163M$6M$-169M$-9.56—

Quarterly results

USD · three months to · source: SEC filings
Revenue, trailing 12 months
$286M
Net income, trailing 12 months
$222M
RevenueNet income
Three months to Mar 2023: revenue $68M, net income $-32M$68MMar ’23Three months to Jun 2023: revenue $84M, net income $-6M$84MJun ’23Three months to Sep 2023: revenue $89M, net income $-3M$89MSep ’23

Latest quarter to Sep 2023: revenue $89M, net income $-3M. Trailing 12 months to Dec 2022.

SEC filings

Official filings of Intercept Pharmaceuticals with the US Securities and Exchange Commission.

Annual results

Revenue
$286 M
Operating income
$-68 M
Net income
$222 M

For year ending December-2022 · source: SEC filing

Balance sheet

Total assets
$554 M
Total liabilities
$461 M
Total equity
$93 M

As of December-2022

Insider trading at Intercept Pharmaceuticals#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$0
0 purchases, 0 insiders
Sold, 12 months
$0
0 sales, 0 insiders
Net, 12 months
$0
open market only
Insiders on file
43
since
Intercept Pharmaceuticals: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Jerome Benedict DursoCEO, DirectorTender in a change of control-51,815$19.00$984 K0Form 4
filed Keith Michael GottesdienerDirectorTender in a change of control-24,719$19.00$470 K0Form 4
filed Dagmar Rosa-BjorkesonDirectorTender in a change of control-14,766$19.00$281 K0Form 4
filed Glenn SblendorioDirectorTender in a change of control-23,447$19.00$445 K0Form 4
filed M. Michelle BerreyPresident, R&D and CMOTender in a change of control-28,349$19.00$539 K0Form 4
filed Paolo FundaroDirectorTender in a change of control-35,794$19.00$680 K0Form 4
filed Gino SantiniDirectorTender in a change of control-23,645$19.00$449 K0Form 4
filed Srinivas AkkarajuDirectorTender in a change of control-37,887$19.00$720 K0Form 4

Markets and events: Intercept Pharmaceuticals#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Buybacks, Q4 2021
$0M
Q4 2021

Stock splits: 5.778-for-1 split

Intercept Pharmaceuticals share buybacks by quarter
Buybacks, quarterFiscalSpent
Q4 2021Q4 2021$0M

Intercept Pharmaceuticals scorecard#

Passes 8 of the 15 checks that could be worked out: strongest in profitability (3 of 4), weakest in financial health (1 of 4). Fiscal year 2022.

  • Valuationnot known
  • Growth4 of 6
  • Profitability3 of 4
  • Financial health1 of 4
  • Shareholder returns0 of 1

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 20, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Intercept Pharmaceuticals: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Intercept Pharmaceuticals: statements by fiscal year
PeriodTrendFY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020FY 2019to Dec 31, 2019FY 2018to Dec 31, 2018FY 2017to Dec 31, 2017FY 2016to Dec 31, 2016FY 2015to Dec 31, 2015FY 2014to Dec 31, 2014FY 2013to Dec 31, 2013
Income statement
Revenue286261r234r252180131252.81.7—
Cost of revenue1.01.2r2.4r4.22.51.4————
Research and development177183r189r243207191154113r80r28r
Selling, general and administrative176177r261r31725527427411935—
General and administrative———————10435r13r
Operating expenses————465467427232115—
Total costs and expenses354361r464r564465467—232115r41r
Operating income−68−100r−230r−312−285−336−403−229−113—
Interest expense and finance costs21544841312914———
Other non-operating income (expense)−107−36r−44r−32−24−25−102.7−170r−28r
Income before tax−175−136r−273r−345−309−360−413−226−283−68
Income from discontinued operations39745−1.5———————
Net income including minority interests222−91−275−345−309−360−413———
Net income attributable to shareholders222−91−275−345−309−360−413−226−283r−68r
Earnings per share, basic6.56-2.87-8.34-10.89-10.86-14.38-16.74-9.56-13.63-3.76
Earnings per share, diluted6.56-2.87-8.34-10.89-10.86-14.38-16.74-9.56-13.63-3.76
Shares, weighted average (basic)34323332——————
Shares, weighted average (diluted)3432333228252524r21r18
Balance sheet
Cash and cash equivalents518558r70r4370443320r13r
Short-term investments——412583393—————
Receivables2728r423826179.1———
Inventory6.57.9r9.08.57.13.52.3———
Other current assets2223r272621179.4146.1r2.7
Current assets540508r546721482448708642246r148
Property, plant and equipment1.03.3r6.35.2101611105.9r1.7
Right-of-use (leased) assets—6.11213——————
Total assets554527580755509484739656254r150
Accounts payable1418r2519127.06.74.23.13.2
Debt due within a year1100————————
Current liabilities230168r179162114104794715r8.9
Long-term debt223540561532371356341———
Lease liabilities (non-current)—4.47.79.2——————
Total liabilities4617117477034904684245423r68
Retained earnings−2,137−2,490−2,398−2,123−1,779−1,470−1,108−696−469r−186
Shareholders' equity93−184−167521916315602231r82r
Total liabilities and equity554527580755509484739656254r150
Shares outstanding42303333302525242119
Cash-flow statement
Depreciation and amortization————————0.40.1
Share-based compensation2228r49r565057463420r9.4r
Cash from operating activities−27−41r−172r−237−241−265−342−163−88−28
Capital expenditure−0.6−0.4−3.9−1.1−0.2−10−5.1−5.9−4.6r−1.6r
Cash from investing activities26271163−189−48288−60−389−97−70
Shares issued———227261——559183r61r
Shares bought back—−76————————
Cash from financing activities−2671.1−0.74582642.841456519166
Exchange-rate effect on cash−6.3−2.0r0.6r−0.4−1.51.1−0.9−0.4——
Change in cash−3929−9.132−272611136.7r−32r
Report10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

As of Sep 30, 2023

Events at Intercept Pharmaceuticals#

What the company reported to the SEC within four business days (Form 8-K), newest first.

No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.

Debt called early 1 · Restructuring 1 · Taken over and delisted 1 · Change in control 1 · Acquisition or sale completed 1 · Directors and officers 2 · Material agreement 8 · Unregistered share sale 6 · Shareholder rights changed 1 · Bylaws or fiscal year changed 1 · Shareholder vote 1 · Results announced 5

Intercept Pharmaceuticals: events reported to the SEC
FiledWhat happenedFiling
Debt called earlyTaken over and delistedChange in controlAcquisition or sale completedDirectors and officersMaterial agreementShareholder rights changedBylaws or fiscal year changed8-K
Material agreement8-K
Results announced8-K
Restructuring8-K
Shareholder vote8-K
Material agreement8-K
Results announced8-K
Material agreement8-K
Results announced8-K
Directors and officers8-K
Results announced8-K
Material agreement8-K
Unregistered share sale8-K
Material agreementUnregistered share sale8-K
Unregistered share sale8-K
Material agreementUnregistered share sale8-K
Unregistered share sale8-K
Material agreementUnregistered share sale8-K
Results announced8-K

As of Nov 8, 2023

Acquisitions and funding#

1 private funding rounds before listing

Private share sales · funding history

Private share sales of Intercept Pharmaceuticals
MonthRaisedRaiseSizeInvestorsSoldFiling
Aug 2012$30 MNo. 1$10 to $50 million2equitySEC

Lobbying by Intercept Pharmaceuticals#

$0 spent on lobbying the US Congress and federal agencies in 2025.

Lobbying, 2025
$0
#1,526 among companies on value.today
Own lobbyists
No
only outside firms
Firms hired
1
in 2025
2026 so far
$0

Lobbying firms hired in 2025

Sidley Austin LLP

Intercept Pharmaceuticals: lobbying spending by year
YearSpendingOwn lobbyistsReports
2026 (so far)$0—3
2025$0—4
2024$180 K—4
2023$120 K—4
2022$100 K—4

FDA drug approvals: Intercept Pharmaceuticals#

2 approved applications held, 2 of them new molecular entities; 1 approvals and 0 new uses in 2026.

Approvals held
2
New molecular entities
2
New uses approved
0
efficacy supplements
Generics
0
2 new drugs, 0 biologics
Intercept Pharmaceuticals: latest FDA approvals
ApprovedDrugKind
2026-03-17Lynavoynew moleculeLinerixibat · NDA220295New drug (NDA)
2016-05-27Ocalivanew moleculeObeticholic Acid · NDA207999New drug (NDA)

Layoffs at Intercept Pharmaceuticals#

From US state WARN notices and SEC 8-K restructuring filings, newest first.

People, last 12 months
0
0 notices and filings
People, all years
172
2020–2023
Latest
—
2023-06-22
Intercept Pharmaceuticals: people laid off by year and month
YearJanFebMarAprMayJunJulAugSepOctNovDecTotal
2023············—
2020·······1702···172
Intercept Pharmaceuticals: latest layoffs
AnnouncedPeopleKindWhereSource
Not statedRestructuring planSEC 8-KCompany-wide planFiling
effective 2 peopleLayoffWARN noticeSan Diego County, CaliforniaNotice list
170 peopleRestructuring planSEC 8-K“The Plan will result in a workforce reduction of approximately 25%, or approximately 170 employees.”Filing

How Intercept Pharmaceuticals compares in Biotechnology

  • Revenue$286 M · higher than 81% of 647
  • Net margin77.6% · higher than 99% of 408
  • Revenue growth9.6% · higher than 53% of 438

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
Intercept Pharmaceuticals🇺🇸$447 M—77.6%+9.6%
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

How current the figures are

Market cap:
Jul 30, 2023 (last known)
Annual results:
For year ending December-2022
Balance sheet:
As of December-2022
Employees:
As on 2021
Profile updated:
Nov 16, 2026

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Intercept Pharmaceuticals? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Intercept Pharmaceuticals's ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Intercept Pharmaceuticals? Suggest a correction